Finally, studies on bevacizumab (65, 66) showed that this VEGF-targeted agent could stimulate the maturation of DCs and decrease Tregs in clinical trials and reduce MDSCs in the tumor site in animal models of RCC (67). The gene discussed is VEGFA; the disease is neoplasm.